RxDoctor Payments Data

Hina Siddiqui, MD

Clinical Cardiac Electrophysiology · The Woodlands, TXNPI 1770620957

Payments from drug & device makers

$21,231in general payments, 2019–2025

Across 430 payments — averaging $49.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$18K
  • Impulse Dynamics (USA) Inc.$828
  • Biosense Webster, Inc.$249
  • Johnson & Johnson$248
  • Pfizer$207
  • Irhythm Technologies, Inc.$193
  • plus $1K from 16 others

What the payments were for

  • Consulting fees$3,05614%
  • Travel & lodging$5,80827%
  • Food & beverage$12,21058%
  • Education$1251%
  • Other$330%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,231 in reported general payments places this provider in the 30th percentile of 233 clinical cardiac electrophysiology providers in Texas.

See all clinical cardiac electrophysiology providers in Texas

Medicare billing

Part B allowed, 2024
$74,168
Medicare patients
500
Services billed
1,654

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban160$181,292
EliquisApixaban72$69,836
MultaqDronedarone Hcl23$20,242
TrulicityDulaglutide11$10,410
Dofetilide21$4,017
Flecainide Acetate59$3,853
SotalolSotalol Hcl93$1,827
Diltiazem 12hr ErDiltiazem Hcl12$1,206
Potassium Chloride80$1,159
Metoprolol Succinate73$1,144
Digoxin66$994
Losartan Potassium51$844
Minocycline Hcl50$809
Carvedilol66$782
Metoprolol Tartrate105$687

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$248$181,292160 claims
PfizerEliquis$207$69,83672 claims
Sanofi-aventis U.S. LLCMultaq$97$20,24223 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 233 clinical cardiac electrophysiology providers in Texas.

Other clinical cardiac electrophysiology in The Woodlands

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →